Clinical Trial Evaluates Tocilizumab for COVID-19 Pneumonia: Baylor College of Medicine
April 29, 2020
April 29, 2020
HOUSTON, Texas, April 29 -- The Baylor College of Medicine issued the following news release:
Baylor College of Medicine is a research site for a clinical trial evaluating the therapeutic benefit and safety of Tocilizumab (TCZ), an immunomodulator drug, in patients with severe COVID-19 pneumonia.
The Baylor site is enrolling patients who are hospitalized at Baylor St. Luke's Medical Center and Harris Health System's Ben Taub Hospital.
"The organ most c . . .
Baylor College of Medicine is a research site for a clinical trial evaluating the therapeutic benefit and safety of Tocilizumab (TCZ), an immunomodulator drug, in patients with severe COVID-19 pneumonia.
The Baylor site is enrolling patients who are hospitalized at Baylor St. Luke's Medical Center and Harris Health System's Ben Taub Hospital.
"The organ most c . . .